FY25 result
FindiMay 30, 2025FND’s FY25 revenue beat guidance expectations (A$75m vs A$68m to A$70m)., whilst reported EBITDA came in at the mid-point of guidance (A$30m-A$32m). We saw this as a somewhat mixed result. While the headline numbers faired well versus guidance parameters they were assisted by higher “other income.” More positively F25 Operating cashflow generation was strong and FND’s India IPO remains on track. We lower our FND FY26F/FY27F EPS by >10% off low bases. Our target price falls to A$7.55 (previously A$8.35) on our earnings changes. We think FND management are executing well on the company’s overall build out, and with significant upside potential existing to our price target, we maintain our ADD call. We lower our FND FY26F/FY27F EPS by >10% off low bases. Our target price falls to A$7.55 (previously A$8.35) on our earnings changes.
- Forums
- ASX - By Stock
- May 28th Earnings expectations and guidance
FND
findi limited
Add to My Watchlist
0.24%
!
$4.17

FY25 resultFindiMay 30, 2025FND’s FY25 revenue beat guidance...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.17 |
Change
0.010(0.24%) |
Mkt cap ! $257.7M |
Open | High | Low | Value | Volume |
$4.20 | $4.29 | $4.12 | $370.0K | 88.29K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5122 | $4.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.40 | 11620 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1210 | 4.120 |
1 | 1898 | 4.110 |
2 | 10000 | 4.100 |
1 | 4000 | 4.050 |
4 | 7496 | 4.000 |
Price($) | Vol. | No. |
---|---|---|
4.400 | 11620 | 1 |
4.440 | 5000 | 1 |
4.570 | 1666 | 1 |
4.580 | 622 | 1 |
4.590 | 800 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
FND (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online